How To Choose A Biologics CDMO: The 4 Selection Criteria According To Ralf Otto, CDMO Operations Expert And Rezon Bio's COO

Selecting the right contract development and manufacturing organization (CDMO) determines whether a biologic reaches the market on schedule or faces costly development stalls. Evaluating potential partners requires evaluating four crucial dimensions: proven technical track record, transparent communication practices, flexible manufacturing infrastructure, and a true partnership mindset.

Technical expertise ensures smooth navigation of complex analytics and process scaling. Open communication eliminates project surprises through proactive problem-solving. Facilities must offer adaptable scale capabilities—from agile early-stage clinical trial supply to larger commercial capacity—to prevent disruptive site transfers later. Finally, aligning with a team that operates as an invested partner rather than a transactional vendor protects project momentum.

Evaluating CDMO options against these operational criteria mitigates manufacturing risk and streamlines biotherapeutic commercialization. Explore the four selection criteria to optimize your outsourcing strategy.